{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T01:54:15Z","timestamp":1769738055206,"version":"3.49.0"},"reference-count":58,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"},{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Womens Health (Lond Engl)"],"published-print":{"date-parts":[[2006,5]]},"abstract":"<jats:p> Osteoporosis-related fractures are a major public health problem worldwide. Antiresorptive drugs, which work principally by suppressing bone resorption, are the established therapeutic approach for the prevention of fragility fractures in patients with osteoporosis. Parathyroid hormone and its analogs represent a new class of agents with anabolic effects on the skeleton. The results of double-blind, randomized, placebo-controlled trials have shown that both the full length, 84 amino acid parathyroid hormone and teriparatide, the parathyroid hormone fragment (1\u201334) increase bone mineral density and reduce the risk of fracture when administered intermittently to postmenopausal osteoporotic women. Therefore, these drugs should be considered an alternative therapy in postmenopausal osteoporosis. <\/jats:p>","DOI":"10.2217\/17455057.2.3.447","type":"journal-article","created":{"date-parts":[[2006,4,25]],"date-time":"2006-04-25T18:18:23Z","timestamp":1145989103000},"page":"447-457","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Parathyroid Hormone (1\u201384) and Teriparatide in the Treatment of Postmenopausal Osteoporosis"],"prefix":"10.1177","volume":"2","author":[{"given":"C\u00e9sar E","family":"Bogado","sequence":"first","affiliation":[{"name":"Instituto de Investigaciones Metab\u00f3licas, Libertad 836, C1012 Buenos Aires, Argentina, Tel.: +54 11 5031 9755; Fax: +54 11 4815 6556;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio E","family":"Massari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 R","family":"Zanchetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2006,5,1]]},"reference":[{"key":"bibr0101-17455057.2.3.447","unstructured":"Papers of special note have been highlighted as either of interest (\u2022) or of considerable interest (\u2022\u2022) to readers."},{"key":"bibr1-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90218-E"},{"key":"bibr2-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.6.785"},{"key":"bibr3-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650070902"},{"key":"bibr4-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650100202"},{"key":"bibr5-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.22.2815"},{"key":"bibr6-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/20.6.435"},{"key":"bibr7-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1997.12.1.24"},{"key":"bibr8-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-003-1385-4"},{"key":"bibr9-17455057.2.3.447","volume-title":"Mortality, Service Use, Expenditures and Long-term Functional Impairment.","author":"Office of Technology Assessment of the United States","year":"1993"},{"key":"bibr10-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-002-1314-y"},{"key":"bibr11-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08657-9"},{"key":"bibr12-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1007\/s001980070075"},{"key":"bibr13-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1210\/endo-110-2-506"},{"key":"bibr14-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.280.6228.1340"},{"key":"bibr010001-17455057.2.3.447","unstructured":"First report on the bone anabolic actions of parathyroid hormone (PTH) in humans"},{"issue":"1","key":"bibr15-17455057.2.3.447","first-page":"58","volume":"16","author":"Watson PH","year":"1993","journal-title":"Clin. Invest. Med."},{"key":"bibr16-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1210\/endo-99-6-1645"},{"key":"bibr17-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650090403"},{"key":"bibr18-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1210\/endo.142.2.7955"},{"key":"bibr19-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1992.tb02323.x"},{"key":"bibr20-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1016\/8756-3282(93)90190-L"},{"key":"bibr21-17455057.2.3.447","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1359\/jbmr.2001.16.10.1846","volume":"16","author":"Dempster DW","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"bibr22-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2005.03.018"},{"key":"bibr010002-17455057.2.3.447","unstructured":"Interesting approach to the molecular mechanism behind PTH bone anabolic effects"},{"issue":"2","key":"bibr23-17455057.2.3.447","first-page":"620","volume":"82","author":"Hodsman AB","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"bibr24-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199412153312404"},{"issue":"6","key":"bibr25-17455057.2.3.447","first-page":"2127","volume":"85","author":"Horwitz M","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"bibr26-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020334"},{"key":"bibr27-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030768"},{"key":"bibr28-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2003.18.3.539"},{"key":"bibr010003-17455057.2.3.447","unstructured":"First in vivo evidence that teriparatide treatment is not detrimental to cortical bone"},{"key":"bibr29-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2005.03.003"},{"key":"bibr30-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031975"},{"key":"bibr010004-17455057.2.3.447","unstructured":"First trial to assess the efficacy of antiresorptive\/anabolic combination therapy"},{"key":"bibr31-17455057.2.3.447","first-page":"S22","volume":"20","author":"Bogado CE","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"bibr32-17455057.2.3.447","volume-title":"Forteo (teriparatide injection). Product labeling","year":"2002"},{"key":"bibr33-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90169-7"},{"key":"bibr34-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105103441904"},{"key":"bibr010005-17455057.2.3.447","unstructured":"Pivotal Phase III trial that led to the approval of teriparatide as a treatment for severe postmenopausal osteoporosis"},{"key":"bibr35-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2003.18.1.18"},{"key":"bibr36-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.18.2024"},{"key":"bibr37-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.050501"},{"key":"bibr38-17455057.2.3.447","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1359\/JBMR.050508","volume":"20","author":"Greenspan SL","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"bibr010006-17455057.2.3.447","unstructured":"First communication on the antifracture efficacy of PTH (1\u201384) in postmenopausal osteoporotic women"},{"key":"bibr39-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1080\/01926230252929882"},{"key":"bibr010007-17455057.2.3.447","unstructured":"Describes the findings of a carcinogenicity study in rats receiving teriparatide"},{"key":"bibr40-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030768"},{"key":"bibr41-17455057.2.3.447","first-page":"S98","volume":"19","author":"Wilker CE","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"bibr42-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.040117"},{"key":"bibr43-17455057.2.3.447","first-page":"S98","volume":"19","author":"Neer R","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"bibr44-17455057.2.3.447","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1359\/jbmr.2003.18.3.539","volume":"18","author":"Zanchetta JR","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"bibr45-17455057.2.3.447","first-page":"S54","volume":"18","author":"Bogado CE","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"bibr46-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050336"},{"key":"bibr47-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050157"},{"key":"bibr48-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.2174\/1381612013397780"},{"key":"bibr49-17455057.2.3.447","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.050605"},{"key":"bibr101-17455057.2.3.447","unstructured":"FDA, CDER, Endocrinologic and Metabolic Drugs Advisory Committee, July 27, 2001 www.fda.gov\/ohrms\/dockets\/ac\/01\/slides\/3761s2_01_lilly"}],"container-title":["Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2217\/17455057.2.3.447","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.2217\/17455057.2.3.447","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2217\/17455057.2.3.447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T14:16:41Z","timestamp":1741616201000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.2217\/17455057.2.3.447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["10.2217\/17455057.2.3.447"],"URL":"https:\/\/doi.org\/10.2217\/17455057.2.3.447","relation":{},"ISSN":["1745-5057","1745-5065"],"issn-type":[{"value":"1745-5057","type":"print"},{"value":"1745-5065","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}